$784 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 128 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGN | ALLERGAN PLC | $48,138,000 | -10.4% | 177,100 | 0.0% | 6.14% | +16.7% | |
| VNDA | VANDA PHARMACEUTICALS INC | $5,791,000 | -11.1% | 513,390 | 0.0% | 0.74% | +15.8% | |
| ALDR | ALDER BIOPHARMACEUTICALS INC | $4,095,000 | -38.2% | 125,000 | 0.0% | 0.52% | -19.6% | |
| UTHR | UNITED THERAPEUTICS CORP DEL | $3,785,000 | -24.6% | 28,840 | 0.0% | 0.48% | -1.6% | |
| BLCM | BELLICUM PHARMACEUTICALS INC | $3,364,000 | -31.7% | 231,514 | 0.0% | 0.43% | -11.0% | |
| KITE | KITE PHARMA INC | $3,172,000 | -8.7% | 56,970 | 0.0% | 0.40% | +19.1% | |
| ICPT | INTERCEPT PHARMACEUTICALS IN | $2,903,000 | -31.3% | 17,500 | 0.0% | 0.37% | -10.6% | |
| FOMX | FOAMIX PHARMACEUTICALS LTD | $2,785,000 | -28.5% | 380,000 | 0.0% | 0.36% | -7.1% | |
| BITI | BIOTIE THERAPIES OYJsponsored adr | $2,576,000 | -34.5% | 196,800 | 0.0% | 0.33% | -14.5% | |
| XLRN | ACCELERON PHARMA INC | $2,490,000 | -21.3% | 100,000 | 0.0% | 0.32% | +2.6% | |
| QURE | UNIQURE NV | $2,352,000 | -24.3% | 115,000 | 0.0% | 0.30% | -1.3% | |
| SCYX | SCYNEXIS INC | $2,279,000 | -17.2% | 313,000 | 0.0% | 0.29% | +8.2% | |
| LIFE | ATYR PHARMA INC | $2,145,000 | -42.0% | 209,027 | 0.0% | 0.27% | -24.3% | |
| SMMT | SUMMIT THERAPEUTICS PLCspons ads | $2,136,000 | -6.3% | 205,200 | 0.0% | 0.27% | +22.4% | |
| HALO | HALOZYME THERAPEUTICS INC | $2,015,000 | -40.5% | 150,000 | 0.0% | 0.26% | -22.6% | |
| TRILLIUM THERAPEUTICS INC | $1,915,000 | -40.3% | 147,000 | 0.0% | 0.24% | -22.3% | ||
| ALDX | ALDEYRA THERAPEUTICS INC | $1,545,000 | -24.9% | 265,000 | 0.0% | 0.20% | -2.0% | |
| CBYL | CARBYLAN THERAPEUTICS INC | $1,428,000 | -50.1% | 400,000 | 0.0% | 0.18% | -35.0% | |
| TBRA | TOBIRA THERAPEUTICS INC | $1,329,000 | -44.0% | 137,622 | 0.0% | 0.17% | -27.0% | |
| CLCD | COLUCID PHARMACEUTICALS INC | $1,228,000 | -56.5% | 317,250 | 0.0% | 0.16% | -43.3% | |
| GNVC | GENVEC INC | $832,000 | +13.2% | 360,325 | 0.0% | 0.11% | +47.2% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.